Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) saw unusually-strong trading volume on Monday . Approximately 1,152,607 shares were traded during trading, an increase of 55% from the previous session’s volume of 744,649 shares.The stock last traded at $47.61 and had previously closed at $46.96.
PTCT has been the subject of a number of recent research reports. Barclays reiterated a “hold” rating and issued a $43.00 target price on shares of PTC Therapeutics in a report on Monday, August 12th. SunTrust Banks began coverage on PTC Therapeutics in a report on Tuesday, November 12th. They set a “buy” rating and a $78.00 price objective on the stock. TheStreet raised shares of PTC Therapeutics from a “d” rating to a “c-” rating in a research note on Tuesday, October 29th. Citigroup set a $62.00 price target on shares of PTC Therapeutics and gave the stock a “buy” rating in a research report on Thursday, September 26th. Finally, ValuEngine raised PTC Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $54.38.
The company has a market cap of $3.07 billion, a P/E ratio of -26.94 and a beta of 1.90. The company’s 50-day moving average price is $41.56 and its two-hundred day moving average price is $41.85. The company has a current ratio of 4.40, a quick ratio of 4.30 and a debt-to-equity ratio of 0.44.
PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.91) by ($0.15). The firm had revenue of $71.40 million during the quarter, compared to the consensus estimate of $72.03 million. PTC Therapeutics had a negative net margin of 74.86% and a negative return on equity of 31.92%. The firm’s quarterly revenue was up 33.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.06) earnings per share. As a group, analysts anticipate that PTC Therapeutics, Inc. will post -2.86 earnings per share for the current year.
Institutional investors have recently added to or reduced their stakes in the business. State of New Jersey Common Pension Fund D acquired a new stake in shares of PTC Therapeutics in the 3rd quarter worth approximately $1,809,000. Pictet Asset Management Ltd. raised its holdings in shares of PTC Therapeutics by 3.5% during the third quarter. Pictet Asset Management Ltd. now owns 1,161,775 shares of the biopharmaceutical company’s stock worth $39,291,000 after acquiring an additional 39,302 shares in the last quarter. Sector Gamma AS boosted its position in PTC Therapeutics by 17.8% during the second quarter. Sector Gamma AS now owns 229,498 shares of the biopharmaceutical company’s stock valued at $10,327,000 after purchasing an additional 34,755 shares during the last quarter. Aperio Group LLC acquired a new stake in PTC Therapeutics during the second quarter valued at $168,000. Finally, Russell Investments Group Ltd. boosted its position in PTC Therapeutics by 513.3% during the third quarter. Russell Investments Group Ltd. now owns 58,401 shares of the biopharmaceutical company’s stock valued at $1,975,000 after purchasing an additional 48,879 shares during the last quarter. 99.35% of the stock is owned by hedge funds and other institutional investors.
PTC Therapeutics Company Profile (NASDAQ:PTCT)
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.
See Also: What does an outperform rating mean?
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.